Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 28, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Population at Risk Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jun 28, 2026, 7:24 AM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 28, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

NCT05126303
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
RMC-035, Placebo
Drug
Lead sponsor
Guard Therapeutics AB
Industry
Eligibility
18 Years to 84 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

NCT01243424
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin, glimepiride, linagliptin placebo, glimepiride placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
6,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
177
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Not applicable Interventional

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

NCT02347670
View directory record Official record
Conditions
Glaucoma
Interventions
Efficacy-patient navigator to improve follow-up adherence, Office-Based Usual Care
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
50 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

NCT01445613
View directory record Official record
Conditions
Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
Interventions
RX Acculink Carotid Stent System (RX Acculink)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
AVI-014 versus Filgrastim
Drug
Lead sponsor
AviGenics
Industry
Eligibility
18 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Jun 28, 2026, 7:24 AM EDT
Completed No phase listed Observational

Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?

NCT00468494
View directory record Official record
Conditions
General Anesthesia, Hyperglycemia
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Jun 28, 2026, 7:24 AM EDT
Completed No phase listed Observational

A Pilot Study of the Envision® Surface

NCT00405834
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Envision® Patient Support System
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 2Phase 3 Interventional

Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV

NCT01607541
View directory record Official record
Conditions
HIV/AIDS
Interventions
BCAP peer-driven intervention (PDI), Control intervention
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 60 Years
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jun 28, 2026, 7:24 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jun 28, 2026, 7:24 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Diclofenac/Misoprostol
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Jun 28, 2026, 7:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

NCT02419716
View directory record Official record
Conditions
Colorectal Cancer Screening, Colorectal Cancer
Interventions
Cologuard
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
40
States / cities
Glendale, Arizona • Mesa, Arizona • Tempe, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jun 28, 2026, 7:24 AM EDT
Completed No phase listed Observational

Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population

NCT00845416
View directory record Official record
Conditions
Severe Combined Immunodeficiency, T Cell Lymphocytopenia
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 30 Days
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chinle, Arizona • Tuba City, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

NCT00334152
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Interventions
casopitant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
25
States / cities
Fairhope, Alabama • Mobile, Alabama • Montgomery, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Strengthening Families and Reducing Risk Thru Developmental and Legal Collaboration

NCT01343940
View directory record Official record
Conditions
Parenting, Child Rearing, Child Abuse, Child Neglect, Child Development
Interventions
Project dulce, Safety intervention
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jun 28, 2026, 7:24 AM EDT
Not listed Not applicable Interventional

Implementing HCV Treatment for High-risk Populations in Austin, Texas

NCT05460130
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simplified Hepatitis C Virus (HCV) Treatment Protocol
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Jun 28, 2026, 7:24 AM EDT
Terminated No phase listed Observational

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

NCT02345421
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 28, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrative Psychosocial Group Treatment

NCT03648177
View directory record Official record
Conditions
Chronic Pain, Opioid Misuse
Interventions
IPGT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jun 28, 2026, 7:24 AM EDT
Enrolling by invitation Not applicable Interventional

Centralized Lung Cancer Screening Engagement in At-Risk Populations

NCT07216144
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Centralized patient outreach for lung cancer screening
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 28, 2026, 7:24 AM EDT
Terminated Phase 3 Interventional Results available

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT00549757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
8,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
118
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jun 28, 2026, 7:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

NCT06926660
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vicadrostat, Empagliflozin, Placebo matching vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 28, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

NCT06450171
View directory record Official record
Conditions
Cancer Predisposition Syndrome, Predisposition, Genetic
Interventions
GRAIL Galleri Test
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 28, 2026, 7:24 AM EDT